Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 14/20 | 0.69 |
| ▸ | ABCC1 | P33527 | 8/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | GBA1 | P04062 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486953 | 0.89 | ABCG2 (0.81) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL5486371 | 0.88 | ABCG2 (0.78) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL5484679 | 0.84 | ABCG2 (0.50) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL6847669 | 0.83 | ABCG2 (0.49) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL6847663 | 0.83 | ABCG2 (0.48) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL5477134 | 0.82 | MEN1 (0.61) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL390423 | 0.81 | ABCG2 (0.74) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL5489502 | 0.76 | ABCG2 (0.64) | ABCG2ABCC1ABCB1RAB9AMEN1 | |
| SCHEMBL5484058 | 0.76 | MEN1 (0.77) | ABCG2RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL13531567 | 0.75 | SLC2A1 (0.78) | ABCG2RAB9AMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226927-B2 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1351691-A4 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6716851-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1351691-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002047690-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | ABCG2 3307/4885ABCC1 1363/4885ABCB1 1421/4885 |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | ABCG2 3290/4885ABCC1 1326/4885ABCB1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.